Global Blood Therapeutics Inc (GBT) Position Increased by Taylor Wealth Management Partners

Share on StockTwits

Taylor Wealth Management Partners lifted its position in Global Blood Therapeutics Inc (NASDAQ:GBT) by 6.2% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 44,788 shares of the company’s stock after buying an additional 2,605 shares during the period. Global Blood Therapeutics makes up about 1.1% of Taylor Wealth Management Partners’ portfolio, making the stock its 26th largest position. Taylor Wealth Management Partners’ holdings in Global Blood Therapeutics were worth $1,839,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. FMR LLC boosted its stake in Global Blood Therapeutics by 21.0% in the 3rd quarter. FMR LLC now owns 7,807,836 shares of the company’s stock worth $296,698,000 after purchasing an additional 1,357,642 shares during the period. Perceptive Advisors LLC boosted its stake in Global Blood Therapeutics by 6.6% in the 3rd quarter. Perceptive Advisors LLC now owns 5,148,910 shares of the company’s stock worth $195,658,000 after purchasing an additional 320,000 shares during the period. Vanguard Group Inc. boosted its stake in Global Blood Therapeutics by 2.6% in the 3rd quarter. Vanguard Group Inc. now owns 4,202,443 shares of the company’s stock worth $159,693,000 after purchasing an additional 108,137 shares during the period. Vanguard Group Inc boosted its stake in Global Blood Therapeutics by 2.6% in the 3rd quarter. Vanguard Group Inc now owns 4,202,443 shares of the company’s stock worth $159,693,000 after purchasing an additional 108,137 shares during the period. Finally, BlackRock Inc. boosted its stake in Global Blood Therapeutics by 1.1% in the 3rd quarter. BlackRock Inc. now owns 4,186,269 shares of the company’s stock worth $159,079,000 after purchasing an additional 43,507 shares during the period.

Shares of Global Blood Therapeutics stock traded down $0.96 during trading hours on Monday, reaching $44.25. 924 shares of the company’s stock were exchanged, compared to its average volume of 871,849. Global Blood Therapeutics Inc has a fifty-two week low of $30.15 and a fifty-two week high of $68.05. The company has a market cap of $2.24 billion, a price-to-earnings ratio of -16.07 and a beta of 2.12.

Global Blood Therapeutics (NASDAQ:GBT) last issued its earnings results on Tuesday, November 6th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.85) by $0.02. During the same quarter in the prior year, the firm earned ($0.66) earnings per share. Analysts expect that Global Blood Therapeutics Inc will post -3.36 earnings per share for the current year.

GBT has been the subject of a number of recent research reports. Cantor Fitzgerald set a $96.00 price objective on shares of Global Blood Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, October 2nd. BidaskClub upgraded shares of Global Blood Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 9th. Oppenheimer set a $82.00 price objective on shares of Global Blood Therapeutics and gave the stock a “buy” rating in a research note on Monday, December 3rd. ValuEngine downgraded shares of Global Blood Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday. Finally, SunTrust Banks increased their price objective on shares of Global Blood Therapeutics to $90.00 and gave the stock a “positive” rating in a research note on Tuesday, December 4th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and fourteen have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $82.80.

ILLEGAL ACTIVITY WARNING: “Global Blood Therapeutics Inc (GBT) Position Increased by Taylor Wealth Management Partners” was originally posted by Macon Daily and is the sole property of of Macon Daily. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://macondaily.com/2019/01/14/global-blood-therapeutics-inc-gbt-position-increased-by-taylor-wealth-management-partners.html.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.

Further Reading: Different Types of Derivatives

Want to see what other hedge funds are holding GBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Global Blood Therapeutics Inc (NASDAQ:GBT).

Institutional Ownership by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply